1
Prostate and Urologic Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl 4
New Haven, CT 06511
1 of 2
- Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 4New Haven, CT 06511
- Melanoma ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 8New Haven, CT 06511
David A. Braun, MD, PhD
Medical Oncology, Genitourinary Oncology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Internal Medicine and Medical Oncology
Titles
- Assistant Professor of Medicine (Medical Oncology), Louis Goodman and Alfred Gilman Yale Scholar
Education & Training
- InstructorHarvard Medical School (2021)
- PhysicianDana-Farber Cancer Institute (2021)
- Postdoctoral FellowDana-Farber Cancer Institute / Harvard Medical School (2019)
- Chief Medical ResidentBrigham and Women’s Hospital / Harvard Medical School (2017)
- Clinical FellowDana-Farber Cancer Institute / Massachusetts General Hospital / Brigham and Women’s Hospital / Harvard Medical School (2016)
- ResidentBrigham and Women’s Hospital / Harvard Medical School (2015)
- InternBrigham and Women’s Hospital / Harvard Medical School (2014)
- MDIcahn School of Medicine at Mount Sinai (2013)
- PhDCourant Institute of Mathematical Sciences at New York University, Computational Biology (2012)
- ABPrinceton University, Molecular Biology (2006)
Additional Information
Honors & Recognitions
- Trailblazer Award: Kidney Cancer Association (2022)
- Goodman and Gilman Yale Scholar: Yale School of Medicine (2022)
- Spatial Multiomics Award: Akoya Biosciences (2021)
- Sparkathon: Emerging Leaders Igniting Innovation: Society for Immunotherapy of Cancer (SITC) (2021)
- 1st Runner-Up, Clinician Scientist: Immuno-Oncology Young Investigator Forum (2021)
- Next Gen Innovator Award: HemOnc Today (2019)
- John R. Svenson Fellowship: Dana-Farber Cancer Institute (2019)
- Emil Frei Fellowship: Dana-Farber Cancer Institute (2018)
- Fellowship Award for Medical Oncology: Brigham and Women’s Hospital / Harvard Medical School (2016)
- Resident Mentor Award: Brigham and Women’s Hospital / Harvard Medical School (2015)
Board Certifications
- AB of Internal Medicine, Medical Oncology (2020)
- AB of Internal Medicine, Internal Medicine (2016)
Professional Service
- European Society for Medical Oncology (ESMO) Scientific Committee for Investigational Immunotherapy Track (2022): Member
- Kidney Caner Association Think Tank (2021): Participant
- Department of Defense Congressionally Directed Medical Research Program Scientific Review Panel (2020 - 2021): Member
- Kidney Cancer Research Summit Steering Committee (2019 - 2020): Committee Member
- Hoosier Cancer Research Network Correlative Science Clinical Trial Working Group (2019 - Present): Member
- American Physician Scientist Association (2009 - 2010): President
Publications
- Systematic Identification of Autosomal and Y-Encoded Minor Histocompatibility Antigens Reveals Predictors of Chronic Gvhd and Candidate GVL TargetsCieri N, Hookeri N, Stromhaug K, Stevens J, Kooshesh K, Klaeger S, Clauser K, Sarkizova S, Braun D, Penter L, Oliveira G, Kim H, Lane W, Li S, Livak K, Ho V, Ritz J, Soiffer R, Keskin D, Stewart C, Gusev A, Getz G, Wu C. Systematic Identification of Autosomal and Y-Encoded Minor Histocompatibility Antigens Reveals Predictors of Chronic Gvhd and Candidate GVL Targets Blood 2022, 140: 4762-4764. DOI: 10.1182/blood-2022-162841.
- 115 Spatial dissection of T cell clonotype identity, transcriptional profiles, and cell-cell interactions in the tumor microenvironment and tertiary lymphoid structuresIorgulescu B, Liu S, Li S, Borji M, Barrera-Lopez I, Shanmugam V, Lyu H, Morriss J, Garcia Z, Murray E, Reardon D, Yoon C, Braun D, Livak K, Wu C, Chen F. 115 Spatial dissection of T cell clonotype identity, transcriptional profiles, and cell-cell interactions in the tumor microenvironment and tertiary lymphoid structures 2022, a127-a127. DOI: 10.1136/jitc-2022-sitc2022.0115.
- Liu S, Iorgulescu J, Li S, Borji M, Barrera-Lopez I, Shanmugam V, Lyu H, Morriss J, Garcia Z, Murray E, Reardon D, Yoon C, Braun D, Livak K, Wu C, Chen F. Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response Immunity 2022, 55: 1940-1952.e5. PMID: 36223726, PMCID: PMC9745674, DOI: 10.1016/j.immuni.2022.09.002.
- 252P Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experienceLabaki C, Bakouny Z, Sanglier T, Schmidt A, Shim J, Braun D, Bouquet F, Joyce M, Xie W, Tolaney S, Choueiri T. 252P Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience Annals Of Oncology 2022, 33: s652. DOI: 10.1016/j.annonc.2022.07.291.
- Denize T, Hou Y, Pignon J, Walton E, West D, Freeman G, Braun D, Wu C, Gupta S, Motzer R, Atkins M, McDermott D, Choueiri T, Shukla S, Signoretti S. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research 2022, 28: 4045-4055. PMID: 35802667, PMCID: PMC9481706, DOI: 10.1158/1078-0432.ccr-22-0923.
- Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors.Adib E, Nassar A, El Zarif T, Kale N, Rakaee M, Mouhieddine T, Abou Alaiwi S, Freeman D, Labban M, Akl E, Haddad R, Hodi F, Sonpavde G, Giannakis M, Braun D, Gusev A, Choueiri T, Overstreet E, Stone E, Kwiatkowski D. Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors. Journal Of Clinical Oncology 2022, 40: 2622-2622. DOI: 10.1200/jco.2022.40.16_suppl.2622.
- Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.Saliby R, Jammihal T, Labaki C, Xie W, Motzer R, Powles T, Rini B, Albiges L, Pal S, McKay R, Signoretti S, Shukla S, Van Allen E, Braun D, Choueiri T. Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience. Journal Of Clinical Oncology 2022, 40: 4531-4531. DOI: 10.1200/jco.2022.40.16_suppl.4531.
- Molecular characterization of the tumor microenvironment in chromophobe renal cell carcinoma (ChRCC) and related oncocytic neoplasms.Labaki C, Zhang L, Hou Y, Bi K, Hobeika C, Bakouny Z, Camp S, Priolo C, Khabibullin D, Schindler N, Alchoueiry M, Denize T, Saliby R, Matar S, Signoretti S, Van Allen E, Shukla S, Braun D, Henske E, Choueiri T. Molecular characterization of the tumor microenvironment in chromophobe renal cell carcinoma (ChRCC) and related oncocytic neoplasms. Journal Of Clinical Oncology 2022, 40: 4549-4549. DOI: 10.1200/jco.2022.40.16_suppl.4549.
- Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience.Labaki C, Bakouny Z, Sanglier T, Schmidt A, Shim J, Braun D, Bouquet F, Joyce M, Xie W, Tolaney S, Choueiri T. Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience. Journal Of Clinical Oncology 2022, 40: 6520-6520. DOI: 10.1200/jco.2022.40.16_suppl.6520.
- Single cell transcriptomic characterization of natural killer (NK) cell populations in clear cell renal cell carcinoma and association with clinical outcomes.Xu W, Bharadwaj M, Birch G, Schindler N, Labaki C, Saliby R, Bakouny Z, Freeman D, O'Toole J, Lee G, McGregor B, Hirsch M, Shukla S, McDermott D, Signoretti S, Romee R, Choueiri T, Braun D. Single cell transcriptomic characterization of natural killer (NK) cell populations in clear cell renal cell carcinoma and association with clinical outcomes. Journal Of Clinical Oncology 2022, 40: e16521-e16521. DOI: 10.1200/jco.2022.40.16_suppl.e16521.
- Fumarate hydratase-deficient renal cell carcinoma: The real-world experience at Dana-Farber Cancer Institute and Moores Cancer Center.Saliby R, Labaki C, Xie W, Nonato T, Schmidt A, Bakouny Z, Xu W, Ravi P, Braun D, Hirsch M, McKay R, Choueiri T, McGregor B. Fumarate hydratase-deficient renal cell carcinoma: The real-world experience at Dana-Farber Cancer Institute and Moores Cancer Center. Journal Of Clinical Oncology 2022, 40: e16522-e16522. DOI: 10.1200/jco.2022.40.16_suppl.e16522.
- Braun DA, Wu CJ. Tumor-Infiltrating T Cells — A Portrait New England Journal Of Medicine 2022, 386: 992-994. PMID: 35263526, DOI: 10.1056/nejmcibr2119477.
- Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report.Atkins M, Jegede O, Haas N, McDermott D, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Ornstein M, Hurwitz M, Peace D, Signoretti S, Denize T, Cimadamore A, Braun D, Wu C, Einstein D, Catalano P, Hammers H. Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report. Journal Of Clinical Oncology 2022, 40: 288-288. DOI: 10.1200/jco.2022.40.6_suppl.288.
- 76 Spatial mapping of T cell receptors and transcriptomes in renal cell carcinoma following immune checkpoint inhibitor therapyLiu S, Iorgulescu B, Li S, Morriss J, Borji M, Murray E, Braun D, Livak K, Wu C, Chen F. 76 Spatial mapping of T cell receptors and transcriptomes in renal cell carcinoma following immune checkpoint inhibitor therapy Journal For ImmunoTherapy Of Cancer 2021, 9: a84-a85. DOI: 10.1136/jitc-2021-sitc2021.076.
- 655 Landscape of helper and regulatory CD4+ T cells in melanomaOliveira G, Stromhaug K, Klaeger S, Cieri N, Iorgulescu B, Li S, Braun D, Neuberg D, Carr S, Livak K, Tompers D, Fritsch E, Wind-Rotolo M, Hacohen N, Sade-Feldman M, Keskin D, Ott P, Rodig S, Boland G, Wu C. 655 Landscape of helper and regulatory CD4+ T cells in melanoma Journal For ImmunoTherapy Of Cancer 2021, 9: a684-a684. DOI: 10.1136/jitc-2021-sitc2021.655.
- Tsai F, Guercio B, Stuver S, Stern R, Peluso M, Winkler M, Piawah S, Vallurupalli M, Luskin M, Braun D, Parent A, Glotzbecker B, Kilbridge K. Resident-Reported Impact of a Novel Oncology Curriculum for Internal Medicine Residents Journal Of Cancer Education 2021, 37: 1879-1885. PMID: 34480712, PMCID: PMC8417651, DOI: 10.1007/s13187-021-02055-6.
- Abstract 62: Development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC)Wang Y, Buck A, Grimaud M, Kodangattil S, Razimbaud C, Fayed A, Chang M, Culhane A, Braun D, Choueiri T, Wu C, Wei K, Chan L, Piel B, Ivanova E, Paweletz C, Barbie D, Jennings R, Ficial M, Sticco-Ivins M, Signoretti S, Freeman G, Zhu Q, Marasco W. Abstract 62: Development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC) Cancer Research 2021, 81: 62-62. DOI: 10.1158/1538-7445.am2021-62.
- Effect of high-dose corticosteroid use on efficacy of immune checkpoint inhibitors in patients with renal cell carcinoma (RCC).Labaki C, Alaiwi S, Schmidt A, Zarif T, Bakouny Z, Nuzzo P, Xu W, Braun D, McGregor B, Choueiri T. Effect of high-dose corticosteroid use on efficacy of immune checkpoint inhibitors in patients with renal cell carcinoma (RCC). Journal Of Clinical Oncology 2021, 39: 4583-4583. DOI: 10.1200/jco.2021.39.15_suppl.4583.
- Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) (CaNI) for advanced renal cell carcinoma with variant histology (aRCCVH).McGregor B, Xie W, Bilen M, Braun D, Xu W, Ravi P, Heath E, McDermott D, McKay R, Hammers H, Choueiri T. Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) (CaNI) for advanced renal cell carcinoma with variant histology (aRCCVH). Journal Of Clinical Oncology 2021, 39: tps4592-tps4592. DOI: 10.1200/jco.2021.39.15_suppl.tps4592.
- Achieve clear cell renal cell carcinoma (CCRCC) cures through dual-targeted fine-tuned immune restoring (DFIR) CAR-T cell therapyWang Y, Buck A, Grimaud M, Kodangattil S, Razimbaud C, Fayed A, Chang M, Culhane A, Braun D, Choueiri T, Wu C, Wei K, Chan L, Piel B, Ivanova E, Paweletz C, Barbie D, Jenning R, Ficial M, Sticco-Ivins M, Signoretti S, Freeman G, Zhu Q, Marasco W. Achieve clear cell renal cell carcinoma (CCRCC) cures through dual-targeted fine-tuned immune restoring (DFIR) CAR-T cell therapy Cytotherapy 2021, 23: s93. DOI: 10.1016/s1465324921004126.
- Braun DA, Street K, Burke KP, Cookmeyer DL, Denize T, Pedersen CB, Gohil SH, Schindler N, Pomerance L, Hirsch L, Bakouny Z, Hou Y, Forman J, Huang T, Li S, Cui A, Keskin DB, Steinharter J, Bouchard G, Sun M, Pimenta EM, Xu W, Mahoney KM, McGregor BA, Hirsch MS, Chang SL, Livak KJ, McDermott DF, Shukla SA, Olsen LR, Signoretti S, Sharpe AH, Irizarry RA, Choueiri TK, Wu CJ. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma Cancer Cell 2021, 39: 632-648.e8. PMID: 33711273, PMCID: PMC8138872, DOI: 10.1016/j.ccell.2021.02.013.
- Braun DA, Bakouny Z, Hirsch L, Flippot R, Van Allen EM, Wu CJ, Choueiri TK. Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma Nature Reviews Clinical Oncology 2021, 18: 199-214. PMID: 33437048, PMCID: PMC8317018, DOI: 10.1038/s41571-020-00455-z.
- Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockadeLi H, Bullock K, Gurjao C, Braun D, Shukla S, Bosse D, Lalani A, Gopal S, Jin C, Horak C, Wind-Rotolo M, Signoretti S, McDermott D, Freeman G, Van Allen E, Schreiber S, Hodi F, Sellers W, Garraway L, Clish C, Choueiri T, Giannakis M. Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockade Cancer Research 2020, 80: ng13-ng13. DOI: 10.1158/1538-7445.am2020-ng13.
- Braun DA, Hou Y, Bakouny Z, Ficial M, Sant’ Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, Steinharter J, Sun M, Wind-Rotolo M, Pignon JC, Cherniack AD, Lichtenstein L, Neuberg D, Catalano P, Freeman GJ, Sharpe AH, McDermott DF, Van Allen EM, Signoretti S, Wu CJ, Shukla SA, Choueiri TK. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma Nature Medicine 2020, 26: 909-918. PMID: 32472114, PMCID: PMC7499153, DOI: 10.1038/s41591-020-0839-y.
- Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE).McKay R, Xie W, McGregor B, Braun D, Wei X, Kyriakopoulos C, Zakharia Y, Maughan B, Rose T, Stadler W, McDermott D, Harshman L, Choueiri T. Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE). Journal Of Clinical Oncology 2020, 38: 5005-5005. DOI: 10.1200/jco.2020.38.15_suppl.5005.
- Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.Braun D, Hou Y, Bakouny Z, Ficial M, Sant'Angelo M, Ross-Macdonald P, Jegede O, Sun M, Wind-Rotolo M, Pignon J, Neuberg D, Catalano P, Freeman G, Sharpe A, McDermott D, Van Allen E, Signoretti S, Wu C, Shukla S, Choueiri T. Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade. Journal Of Clinical Oncology 2020, 38: 5010-5010. DOI: 10.1200/jco.2020.38.15_suppl.5010.
- Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.Ficial M, Jegede O, Sant'Angelo M, Moreno S, Braun D, Wind-Rotolo M, Pignon J, Catalano P, Sun M, Van Allen E, Freeman G, Sharpe A, Hodi F, Motzer R, Wu C, Atkins M, McDermott D, Shukla S, Choueiri T, Signoretti S. Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial. Journal Of Clinical Oncology 2020, 38: 5023-5023. DOI: 10.1200/jco.2020.38.15_suppl.5023.
- Safety and efficacy of retreatment with immune checkpoint inhibitors (ICIs) in patients with metastatic RCC (mRCC) who have previously received an ICI.Ravi P, Bakouny Z, Flippot R, Braun D, Abou Alaiwi S, Wei X, McGregor B, Kilbridge K, Choudhury A, Harshman L, Choueiri T. Safety and efficacy of retreatment with immune checkpoint inhibitors (ICIs) in patients with metastatic RCC (mRCC) who have previously received an ICI. Journal Of Clinical Oncology 2020, 38: 698-698. DOI: 10.1200/jco.2020.38.6_suppl.698.
- Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI).Bakouny Z, Braun D, Shukla S, Pan W, Gao X, Hou Y, Flaifel A, Nassar A, Abou Alaiwi S, Flippot R, Steinharter J, Nuzzo P, Ishii Y, Ross-Macdonald P, Lee G, McDermott D, Heng D, Signoretti S, Van Allen E, Choueiri T. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI). Journal Of Clinical Oncology 2020, 38: 715-715. DOI: 10.1200/jco.2020.38.6_suppl.715.
- Soluble PD-L1 as a marker of progressive disease on nivolumab in kidney cancer.Mahoney K, Ross-Macdonald P, Shukla S, Braun D, Song L, Veras E, Wind-Rotolo M, Van Allen E, McDermott D, Hodi F, Choueiri T, Freeman G. Soluble PD-L1 as a marker of progressive disease on nivolumab in kidney cancer. Journal Of Clinical Oncology 2020, 38: 746-746. DOI: 10.1200/jco.2020.38.6_suppl.746.
- Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial.Flippot R, Bakouny Z, Wei X, Braun D, McGregor B, Steinharter J, Harshman L, Vaishampayan U, Severgnini M, McDermott D, Hodi F, Lee G, Van Allen E, Signoretti S, Choueiri T, McKay R. Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial. Journal Of Clinical Oncology 2020, 38: 740-740. DOI: 10.1200/jco.2020.38.6_suppl.740.
- Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs).Abou Alaiwi S, Nassar A, El Bakouny Z, Berchuck J, Nuzzo P, Flippot R, Flaifel A, Steinharter J, Baca S, Margolis C, Vokes N, Du H, Shukla S, Braun D, Signoretti S, Sonpavde G, Kwiatkowski D, Van Allen E, Choueiri T. Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs). Journal Of Clinical Oncology 2019, 37: 103-103. DOI: 10.1200/jco.2019.37.15_suppl.103.
- Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).Bakouny Z, Vokes N, Gao X, Nassar A, Abou Alaiwi S, Flippot R, Bouchard G, Steinharter J, Nuzzo P, Pan W, Flaifel A, Lee G, Braun D, Wei X, Signoretti S, McGregor B, Harshman L, Van Allen E, Choueiri T. Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2019, 37: 4514-4514. DOI: 10.1200/jco.2019.37.15_suppl.4514.
- Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).Pignon J, Jegede O, Shukla S, Braun D, Horak C, Wind-Rotolo M, Ishii Y, Catalano P, Freeman G, Jennings R, De Cubas A, Rathmell K, Choueiri T, Atkins M, McDermott D, Signoretti S. Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC). Journal Of Clinical Oncology 2019, 37: 4568-4568. DOI: 10.1200/jco.2019.37.15_suppl.4568.
- Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).McKay R, McGregor B, Gray K, Steinharter J, Walsh M, Braun D, Flaifel A, VanAllen E, Wei X, Signoretti S, Harshman L, Vaishampayan U, Choueiri T. Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC). Journal Of Clinical Oncology 2019, 37: 548-548. DOI: 10.1200/jco.2019.37.7_suppl.548.
- Bakouny Z, Flippot R, Braun D, Lalani A, Choueiri T. State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era European Urology Focus 2019, 6: 37-40. PMID: 30827939, DOI: 10.1016/j.euf.2019.02.014.
- Iorgulescu J, Braun D, Oliveira G, Keskin D, Wu C. Acquired mechanisms of immune escape in cancer following immunotherapy Genome Medicine 2018, 10: 87. PMID: 30466478, PMCID: PMC6249768, DOI: 10.1186/s13073-018-0598-2.
- LBA34 PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trialsChoueiri T, Flaifel A, Xie W, Braun D, Ficial M, Jennings R, Nassar A, Escudier B, George D, Motzer R, Morris M, Powles T, Wang E, Huang Y, Freeman G, Signoretti S. LBA34 PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials Annals Of Oncology 2018, 29: viii726. DOI: 10.1093/annonc/mdy424.040.
- Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study.Wei X, McKay R, Gray K, Stadler W, McDermott D, McGregor B, Agarwal N, Kyriakopoulos C, Carneiro B, Rose T, Zakharia Y, Braun D, Livak K, Wu C, Van Allen E, Signoretti S, Lang J, Hodi F, Choueiri T, Harshman L. Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study. Journal Of Clinical Oncology 2018, 36: tps4600-tps4600. DOI: 10.1200/jco.2018.36.15_suppl.tps4600.
- Braun D, Wu C. Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies The Cancer Journal 2017, 23: 115-124. PMID: 28410299, PMCID: PMC5856170, DOI: 10.1097/ppo.0000000000000257.
- Braun D, Burke K, Van Allen E. Genomic Approaches to Understanding Response and Resistance to Immunotherapy Clinical Cancer Research 2016, 22: 5642-5650. PMID: 27698000, PMCID: PMC5135569, DOI: 10.1158/1078-0432.ccr-16-0066.
Patient Care Organizations
Titles
- Assistant Professor of Medicine (Medical Oncology), Louis Goodman and Alfred Gilman Yale Scholar
Education & Training
- InstructorHarvard Medical School (2021)
- PhysicianDana-Farber Cancer Institute (2021)
- Postdoctoral FellowDana-Farber Cancer Institute / Harvard Medical School (2019)
- Chief Medical ResidentBrigham and Women’s Hospital / Harvard Medical School (2017)
- Clinical FellowDana-Farber Cancer Institute / Massachusetts General Hospital / Brigham and Women’s Hospital / Harvard Medical School (2016)
- ResidentBrigham and Women’s Hospital / Harvard Medical School (2015)
- InternBrigham and Women’s Hospital / Harvard Medical School (2014)
- MDIcahn School of Medicine at Mount Sinai (2013)
- PhDCourant Institute of Mathematical Sciences at New York University, Computational Biology (2012)
- ABPrinceton University, Molecular Biology (2006)
Additional Information
Honors & Recognitions
- Trailblazer Award: Kidney Cancer Association (2022)
- Goodman and Gilman Yale Scholar: Yale School of Medicine (2022)
- Spatial Multiomics Award: Akoya Biosciences (2021)
- Sparkathon: Emerging Leaders Igniting Innovation: Society for Immunotherapy of Cancer (SITC) (2021)
- 1st Runner-Up, Clinician Scientist: Immuno-Oncology Young Investigator Forum (2021)
- Next Gen Innovator Award: HemOnc Today (2019)
- John R. Svenson Fellowship: Dana-Farber Cancer Institute (2019)
- Emil Frei Fellowship: Dana-Farber Cancer Institute (2018)
- Fellowship Award for Medical Oncology: Brigham and Women’s Hospital / Harvard Medical School (2016)
- Resident Mentor Award: Brigham and Women’s Hospital / Harvard Medical School (2015)
Board Certifications
- AB of Internal Medicine, Medical Oncology (2020)
- AB of Internal Medicine, Internal Medicine (2016)
Professional Service
- European Society for Medical Oncology (ESMO) Scientific Committee for Investigational Immunotherapy Track (2022): Member
- Kidney Caner Association Think Tank (2021): Participant
- Department of Defense Congressionally Directed Medical Research Program Scientific Review Panel (2020 - 2021): Member
- Kidney Cancer Research Summit Steering Committee (2019 - 2020): Committee Member
- Hoosier Cancer Research Network Correlative Science Clinical Trial Working Group (2019 - Present): Member
- American Physician Scientist Association (2009 - 2010): President
Publications
- Systematic Identification of Autosomal and Y-Encoded Minor Histocompatibility Antigens Reveals Predictors of Chronic Gvhd and Candidate GVL TargetsCieri N, Hookeri N, Stromhaug K, Stevens J, Kooshesh K, Klaeger S, Clauser K, Sarkizova S, Braun D, Penter L, Oliveira G, Kim H, Lane W, Li S, Livak K, Ho V, Ritz J, Soiffer R, Keskin D, Stewart C, Gusev A, Getz G, Wu C. Systematic Identification of Autosomal and Y-Encoded Minor Histocompatibility Antigens Reveals Predictors of Chronic Gvhd and Candidate GVL Targets Blood 2022, 140: 4762-4764. DOI: 10.1182/blood-2022-162841.
- 115 Spatial dissection of T cell clonotype identity, transcriptional profiles, and cell-cell interactions in the tumor microenvironment and tertiary lymphoid structuresIorgulescu B, Liu S, Li S, Borji M, Barrera-Lopez I, Shanmugam V, Lyu H, Morriss J, Garcia Z, Murray E, Reardon D, Yoon C, Braun D, Livak K, Wu C, Chen F. 115 Spatial dissection of T cell clonotype identity, transcriptional profiles, and cell-cell interactions in the tumor microenvironment and tertiary lymphoid structures 2022, a127-a127. DOI: 10.1136/jitc-2022-sitc2022.0115.
- Liu S, Iorgulescu J, Li S, Borji M, Barrera-Lopez I, Shanmugam V, Lyu H, Morriss J, Garcia Z, Murray E, Reardon D, Yoon C, Braun D, Livak K, Wu C, Chen F. Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response Immunity 2022, 55: 1940-1952.e5. PMID: 36223726, PMCID: PMC9745674, DOI: 10.1016/j.immuni.2022.09.002.
- 252P Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experienceLabaki C, Bakouny Z, Sanglier T, Schmidt A, Shim J, Braun D, Bouquet F, Joyce M, Xie W, Tolaney S, Choueiri T. 252P Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience Annals Of Oncology 2022, 33: s652. DOI: 10.1016/j.annonc.2022.07.291.
- Denize T, Hou Y, Pignon J, Walton E, West D, Freeman G, Braun D, Wu C, Gupta S, Motzer R, Atkins M, McDermott D, Choueiri T, Shukla S, Signoretti S. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research 2022, 28: 4045-4055. PMID: 35802667, PMCID: PMC9481706, DOI: 10.1158/1078-0432.ccr-22-0923.
- Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors.Adib E, Nassar A, El Zarif T, Kale N, Rakaee M, Mouhieddine T, Abou Alaiwi S, Freeman D, Labban M, Akl E, Haddad R, Hodi F, Sonpavde G, Giannakis M, Braun D, Gusev A, Choueiri T, Overstreet E, Stone E, Kwiatkowski D. Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors. Journal Of Clinical Oncology 2022, 40: 2622-2622. DOI: 10.1200/jco.2022.40.16_suppl.2622.
- Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.Saliby R, Jammihal T, Labaki C, Xie W, Motzer R, Powles T, Rini B, Albiges L, Pal S, McKay R, Signoretti S, Shukla S, Van Allen E, Braun D, Choueiri T. Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience. Journal Of Clinical Oncology 2022, 40: 4531-4531. DOI: 10.1200/jco.2022.40.16_suppl.4531.
- Molecular characterization of the tumor microenvironment in chromophobe renal cell carcinoma (ChRCC) and related oncocytic neoplasms.Labaki C, Zhang L, Hou Y, Bi K, Hobeika C, Bakouny Z, Camp S, Priolo C, Khabibullin D, Schindler N, Alchoueiry M, Denize T, Saliby R, Matar S, Signoretti S, Van Allen E, Shukla S, Braun D, Henske E, Choueiri T. Molecular characterization of the tumor microenvironment in chromophobe renal cell carcinoma (ChRCC) and related oncocytic neoplasms. Journal Of Clinical Oncology 2022, 40: 4549-4549. DOI: 10.1200/jco.2022.40.16_suppl.4549.
- Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience.Labaki C, Bakouny Z, Sanglier T, Schmidt A, Shim J, Braun D, Bouquet F, Joyce M, Xie W, Tolaney S, Choueiri T. Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience. Journal Of Clinical Oncology 2022, 40: 6520-6520. DOI: 10.1200/jco.2022.40.16_suppl.6520.
- Single cell transcriptomic characterization of natural killer (NK) cell populations in clear cell renal cell carcinoma and association with clinical outcomes.Xu W, Bharadwaj M, Birch G, Schindler N, Labaki C, Saliby R, Bakouny Z, Freeman D, O'Toole J, Lee G, McGregor B, Hirsch M, Shukla S, McDermott D, Signoretti S, Romee R, Choueiri T, Braun D. Single cell transcriptomic characterization of natural killer (NK) cell populations in clear cell renal cell carcinoma and association with clinical outcomes. Journal Of Clinical Oncology 2022, 40: e16521-e16521. DOI: 10.1200/jco.2022.40.16_suppl.e16521.
- Fumarate hydratase-deficient renal cell carcinoma: The real-world experience at Dana-Farber Cancer Institute and Moores Cancer Center.Saliby R, Labaki C, Xie W, Nonato T, Schmidt A, Bakouny Z, Xu W, Ravi P, Braun D, Hirsch M, McKay R, Choueiri T, McGregor B. Fumarate hydratase-deficient renal cell carcinoma: The real-world experience at Dana-Farber Cancer Institute and Moores Cancer Center. Journal Of Clinical Oncology 2022, 40: e16522-e16522. DOI: 10.1200/jco.2022.40.16_suppl.e16522.
- Braun DA, Wu CJ. Tumor-Infiltrating T Cells — A Portrait New England Journal Of Medicine 2022, 386: 992-994. PMID: 35263526, DOI: 10.1056/nejmcibr2119477.
- Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report.Atkins M, Jegede O, Haas N, McDermott D, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Ornstein M, Hurwitz M, Peace D, Signoretti S, Denize T, Cimadamore A, Braun D, Wu C, Einstein D, Catalano P, Hammers H. Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report. Journal Of Clinical Oncology 2022, 40: 288-288. DOI: 10.1200/jco.2022.40.6_suppl.288.
- 76 Spatial mapping of T cell receptors and transcriptomes in renal cell carcinoma following immune checkpoint inhibitor therapyLiu S, Iorgulescu B, Li S, Morriss J, Borji M, Murray E, Braun D, Livak K, Wu C, Chen F. 76 Spatial mapping of T cell receptors and transcriptomes in renal cell carcinoma following immune checkpoint inhibitor therapy Journal For ImmunoTherapy Of Cancer 2021, 9: a84-a85. DOI: 10.1136/jitc-2021-sitc2021.076.
- 655 Landscape of helper and regulatory CD4+ T cells in melanomaOliveira G, Stromhaug K, Klaeger S, Cieri N, Iorgulescu B, Li S, Braun D, Neuberg D, Carr S, Livak K, Tompers D, Fritsch E, Wind-Rotolo M, Hacohen N, Sade-Feldman M, Keskin D, Ott P, Rodig S, Boland G, Wu C. 655 Landscape of helper and regulatory CD4+ T cells in melanoma Journal For ImmunoTherapy Of Cancer 2021, 9: a684-a684. DOI: 10.1136/jitc-2021-sitc2021.655.
- Tsai F, Guercio B, Stuver S, Stern R, Peluso M, Winkler M, Piawah S, Vallurupalli M, Luskin M, Braun D, Parent A, Glotzbecker B, Kilbridge K. Resident-Reported Impact of a Novel Oncology Curriculum for Internal Medicine Residents Journal Of Cancer Education 2021, 37: 1879-1885. PMID: 34480712, PMCID: PMC8417651, DOI: 10.1007/s13187-021-02055-6.
- Abstract 62: Development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC)Wang Y, Buck A, Grimaud M, Kodangattil S, Razimbaud C, Fayed A, Chang M, Culhane A, Braun D, Choueiri T, Wu C, Wei K, Chan L, Piel B, Ivanova E, Paweletz C, Barbie D, Jennings R, Ficial M, Sticco-Ivins M, Signoretti S, Freeman G, Zhu Q, Marasco W. Abstract 62: Development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC) Cancer Research 2021, 81: 62-62. DOI: 10.1158/1538-7445.am2021-62.
- Effect of high-dose corticosteroid use on efficacy of immune checkpoint inhibitors in patients with renal cell carcinoma (RCC).Labaki C, Alaiwi S, Schmidt A, Zarif T, Bakouny Z, Nuzzo P, Xu W, Braun D, McGregor B, Choueiri T. Effect of high-dose corticosteroid use on efficacy of immune checkpoint inhibitors in patients with renal cell carcinoma (RCC). Journal Of Clinical Oncology 2021, 39: 4583-4583. DOI: 10.1200/jco.2021.39.15_suppl.4583.
- Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) (CaNI) for advanced renal cell carcinoma with variant histology (aRCCVH).McGregor B, Xie W, Bilen M, Braun D, Xu W, Ravi P, Heath E, McDermott D, McKay R, Hammers H, Choueiri T. Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) (CaNI) for advanced renal cell carcinoma with variant histology (aRCCVH). Journal Of Clinical Oncology 2021, 39: tps4592-tps4592. DOI: 10.1200/jco.2021.39.15_suppl.tps4592.
- Achieve clear cell renal cell carcinoma (CCRCC) cures through dual-targeted fine-tuned immune restoring (DFIR) CAR-T cell therapyWang Y, Buck A, Grimaud M, Kodangattil S, Razimbaud C, Fayed A, Chang M, Culhane A, Braun D, Choueiri T, Wu C, Wei K, Chan L, Piel B, Ivanova E, Paweletz C, Barbie D, Jenning R, Ficial M, Sticco-Ivins M, Signoretti S, Freeman G, Zhu Q, Marasco W. Achieve clear cell renal cell carcinoma (CCRCC) cures through dual-targeted fine-tuned immune restoring (DFIR) CAR-T cell therapy Cytotherapy 2021, 23: s93. DOI: 10.1016/s1465324921004126.
- Braun DA, Street K, Burke KP, Cookmeyer DL, Denize T, Pedersen CB, Gohil SH, Schindler N, Pomerance L, Hirsch L, Bakouny Z, Hou Y, Forman J, Huang T, Li S, Cui A, Keskin DB, Steinharter J, Bouchard G, Sun M, Pimenta EM, Xu W, Mahoney KM, McGregor BA, Hirsch MS, Chang SL, Livak KJ, McDermott DF, Shukla SA, Olsen LR, Signoretti S, Sharpe AH, Irizarry RA, Choueiri TK, Wu CJ. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma Cancer Cell 2021, 39: 632-648.e8. PMID: 33711273, PMCID: PMC8138872, DOI: 10.1016/j.ccell.2021.02.013.
- Braun DA, Bakouny Z, Hirsch L, Flippot R, Van Allen EM, Wu CJ, Choueiri TK. Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma Nature Reviews Clinical Oncology 2021, 18: 199-214. PMID: 33437048, PMCID: PMC8317018, DOI: 10.1038/s41571-020-00455-z.
- Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockadeLi H, Bullock K, Gurjao C, Braun D, Shukla S, Bosse D, Lalani A, Gopal S, Jin C, Horak C, Wind-Rotolo M, Signoretti S, McDermott D, Freeman G, Van Allen E, Schreiber S, Hodi F, Sellers W, Garraway L, Clish C, Choueiri T, Giannakis M. Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockade Cancer Research 2020, 80: ng13-ng13. DOI: 10.1158/1538-7445.am2020-ng13.
- Braun DA, Hou Y, Bakouny Z, Ficial M, Sant’ Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, Steinharter J, Sun M, Wind-Rotolo M, Pignon JC, Cherniack AD, Lichtenstein L, Neuberg D, Catalano P, Freeman GJ, Sharpe AH, McDermott DF, Van Allen EM, Signoretti S, Wu CJ, Shukla SA, Choueiri TK. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma Nature Medicine 2020, 26: 909-918. PMID: 32472114, PMCID: PMC7499153, DOI: 10.1038/s41591-020-0839-y.
- Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE).McKay R, Xie W, McGregor B, Braun D, Wei X, Kyriakopoulos C, Zakharia Y, Maughan B, Rose T, Stadler W, McDermott D, Harshman L, Choueiri T. Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE). Journal Of Clinical Oncology 2020, 38: 5005-5005. DOI: 10.1200/jco.2020.38.15_suppl.5005.
- Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.Braun D, Hou Y, Bakouny Z, Ficial M, Sant'Angelo M, Ross-Macdonald P, Jegede O, Sun M, Wind-Rotolo M, Pignon J, Neuberg D, Catalano P, Freeman G, Sharpe A, McDermott D, Van Allen E, Signoretti S, Wu C, Shukla S, Choueiri T. Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade. Journal Of Clinical Oncology 2020, 38: 5010-5010. DOI: 10.1200/jco.2020.38.15_suppl.5010.
- Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.Ficial M, Jegede O, Sant'Angelo M, Moreno S, Braun D, Wind-Rotolo M, Pignon J, Catalano P, Sun M, Van Allen E, Freeman G, Sharpe A, Hodi F, Motzer R, Wu C, Atkins M, McDermott D, Shukla S, Choueiri T, Signoretti S. Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial. Journal Of Clinical Oncology 2020, 38: 5023-5023. DOI: 10.1200/jco.2020.38.15_suppl.5023.
- Safety and efficacy of retreatment with immune checkpoint inhibitors (ICIs) in patients with metastatic RCC (mRCC) who have previously received an ICI.Ravi P, Bakouny Z, Flippot R, Braun D, Abou Alaiwi S, Wei X, McGregor B, Kilbridge K, Choudhury A, Harshman L, Choueiri T. Safety and efficacy of retreatment with immune checkpoint inhibitors (ICIs) in patients with metastatic RCC (mRCC) who have previously received an ICI. Journal Of Clinical Oncology 2020, 38: 698-698. DOI: 10.1200/jco.2020.38.6_suppl.698.
- Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI).Bakouny Z, Braun D, Shukla S, Pan W, Gao X, Hou Y, Flaifel A, Nassar A, Abou Alaiwi S, Flippot R, Steinharter J, Nuzzo P, Ishii Y, Ross-Macdonald P, Lee G, McDermott D, Heng D, Signoretti S, Van Allen E, Choueiri T. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI). Journal Of Clinical Oncology 2020, 38: 715-715. DOI: 10.1200/jco.2020.38.6_suppl.715.
- Soluble PD-L1 as a marker of progressive disease on nivolumab in kidney cancer.Mahoney K, Ross-Macdonald P, Shukla S, Braun D, Song L, Veras E, Wind-Rotolo M, Van Allen E, McDermott D, Hodi F, Choueiri T, Freeman G. Soluble PD-L1 as a marker of progressive disease on nivolumab in kidney cancer. Journal Of Clinical Oncology 2020, 38: 746-746. DOI: 10.1200/jco.2020.38.6_suppl.746.
- Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial.Flippot R, Bakouny Z, Wei X, Braun D, McGregor B, Steinharter J, Harshman L, Vaishampayan U, Severgnini M, McDermott D, Hodi F, Lee G, Van Allen E, Signoretti S, Choueiri T, McKay R. Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial. Journal Of Clinical Oncology 2020, 38: 740-740. DOI: 10.1200/jco.2020.38.6_suppl.740.
- Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs).Abou Alaiwi S, Nassar A, El Bakouny Z, Berchuck J, Nuzzo P, Flippot R, Flaifel A, Steinharter J, Baca S, Margolis C, Vokes N, Du H, Shukla S, Braun D, Signoretti S, Sonpavde G, Kwiatkowski D, Van Allen E, Choueiri T. Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs). Journal Of Clinical Oncology 2019, 37: 103-103. DOI: 10.1200/jco.2019.37.15_suppl.103.
- Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).Bakouny Z, Vokes N, Gao X, Nassar A, Abou Alaiwi S, Flippot R, Bouchard G, Steinharter J, Nuzzo P, Pan W, Flaifel A, Lee G, Braun D, Wei X, Signoretti S, McGregor B, Harshman L, Van Allen E, Choueiri T. Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2019, 37: 4514-4514. DOI: 10.1200/jco.2019.37.15_suppl.4514.
- Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).Pignon J, Jegede O, Shukla S, Braun D, Horak C, Wind-Rotolo M, Ishii Y, Catalano P, Freeman G, Jennings R, De Cubas A, Rathmell K, Choueiri T, Atkins M, McDermott D, Signoretti S. Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC). Journal Of Clinical Oncology 2019, 37: 4568-4568. DOI: 10.1200/jco.2019.37.15_suppl.4568.
- Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).McKay R, McGregor B, Gray K, Steinharter J, Walsh M, Braun D, Flaifel A, VanAllen E, Wei X, Signoretti S, Harshman L, Vaishampayan U, Choueiri T. Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC). Journal Of Clinical Oncology 2019, 37: 548-548. DOI: 10.1200/jco.2019.37.7_suppl.548.
- Bakouny Z, Flippot R, Braun D, Lalani A, Choueiri T. State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era European Urology Focus 2019, 6: 37-40. PMID: 30827939, DOI: 10.1016/j.euf.2019.02.014.
- Iorgulescu J, Braun D, Oliveira G, Keskin D, Wu C. Acquired mechanisms of immune escape in cancer following immunotherapy Genome Medicine 2018, 10: 87. PMID: 30466478, PMCID: PMC6249768, DOI: 10.1186/s13073-018-0598-2.
- LBA34 PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trialsChoueiri T, Flaifel A, Xie W, Braun D, Ficial M, Jennings R, Nassar A, Escudier B, George D, Motzer R, Morris M, Powles T, Wang E, Huang Y, Freeman G, Signoretti S. LBA34 PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials Annals Of Oncology 2018, 29: viii726. DOI: 10.1093/annonc/mdy424.040.
- Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study.Wei X, McKay R, Gray K, Stadler W, McDermott D, McGregor B, Agarwal N, Kyriakopoulos C, Carneiro B, Rose T, Zakharia Y, Braun D, Livak K, Wu C, Van Allen E, Signoretti S, Lang J, Hodi F, Choueiri T, Harshman L. Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study. Journal Of Clinical Oncology 2018, 36: tps4600-tps4600. DOI: 10.1200/jco.2018.36.15_suppl.tps4600.
- Braun D, Wu C. Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies The Cancer Journal 2017, 23: 115-124. PMID: 28410299, PMCID: PMC5856170, DOI: 10.1097/ppo.0000000000000257.
- Braun D, Burke K, Van Allen E. Genomic Approaches to Understanding Response and Resistance to Immunotherapy Clinical Cancer Research 2016, 22: 5642-5650. PMID: 27698000, PMCID: PMC5135569, DOI: 10.1158/1078-0432.ccr-16-0066.
Patient Care Organizations
1
Prostate and Urologic Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl 4
New Haven, CT 06511
1 of 2
- Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 4New Haven, CT 06511
- Melanoma ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 8New Haven, CT 06511